Keywords: Johnson & Johnson, Janssen, Zytiga, Prostate cancer, USA, EU

Johnson & Johnson units file for new Zytiga use in USA and EU

Article | 18 June 2012

Print This

Janssen Research & Development, a subsidiary of US drugs giant Johnson & Johnson (NYSE: JNJ), has submitted a supplemental New ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in